Cargando…

THE SPASTICITY-RELATED QUALITY OF LIFE 6-DIMENSIONS INSTRUMENT IN UPPER-LIMB SPASTICITY: PART I DEVELOPMENT AND RESPONSIVENESS

OBJECTIVE: To describe the development of the Spasticity-related Quality of Life 6-Dimensions instrument (SQoL-6D) and its sensitivity to clinical change (responsiveness). DESIGN: Multicentre, prospective, longitudinal cohort study at 8 UK sites (NCT03442660). PATIENTS: Adults (n = 104) undergoing f...

Descripción completa

Detalles Bibliográficos
Autores principales: TURNER-STOKES, Lynne, FHEODOROFF, Klemens, JACINTO, Jorge, LAMBERT, Jeremy, DE LA LOGE, Christine, CALVI-GRIES, Françoise, WHALEN, John, LYSANDROPOULOS, Andreas, MAISONOBE, Pascal, ASHFORD, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Foundation for Rehabilitation Information 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862643/
https://www.ncbi.nlm.nih.gov/pubmed/34726763
http://dx.doi.org/10.2340/jrm.v53.690
Descripción
Sumario:OBJECTIVE: To describe the development of the Spasticity-related Quality of Life 6-Dimensions instrument (SQoL-6D) and its sensitivity to clinical change (responsiveness). DESIGN: Multicentre, prospective, longitudinal cohort study at 8 UK sites (NCT03442660). PATIENTS: Adults (n = 104) undergoing focal treatment of upper limb spasticity. METHODS: No condition-specific health-related quality of life tool is available for upper-limb spasticity of any aetiology. The SQoL-6D was developed to fulfil this need, designed to complement the Upper Limb Spasticity Index (which incorporates the Goal Attainment Scaling evaluation of upper limb spasticity [GASeous] tool) with targeted standardised measures. The 6 dimensions of the SQoL-6D (score range 0–4) map onto common treatment goal areas identified in upper-limb spasticity studies. A Total score (0–100) provides overall spasticity-related health status. To assess responsiveness, the SQoL-6D, Global Assessment of Benefit scale and ”GASeous” were administered at enrolment and 8 weeks. RESULTS: Significant differences in mean SQoL-6D Total score change and effect sizes across patients rating ”some benefit” (0.51) and ”great benefit” (0.88) supported responsiveness. CONCLUSION: The SQoL-6D is a promising new measure of health status in upper limb spasticity, that enables systematic assessment of the impact of this condition in relation to patients’ priority treatment goals. A psychometric evaluation of SQoL-6D is presented separately.